Simple Summary Somatostatin receptors (SSTs) are of particular interest in oncology
because these proteins are overexpressed on the cell membranes of different human …

Somatostatin and its octapeptide analogues exert their effects through interaction with
somatostatin receptor (sst) subtypes 1 through 5 (sst 1–5). Somatostatin binds with high …

Identified in 1973, somatostatin (SST) is a cyclic hormone peptide with a short biological half-
life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five …

Somatostatin (SST) receptors (SSTRs) belong to the typical 7‐transmembrane domain
family of G‐protein‐coupled receptors. Five distinct subtypes (termed SSTR1‐5) have been …

A variety of radiolabeled somatostatin analogs have been developed for targeting of
somatostatin receptor (sst)–positive tumors. Bicyclic somatostatin-based radiopeptides have …

Purpose Targeting of tumours positive for somatostatin receptors (sst) with radiolabelled
peptides is of interest for tumour localization, staging, therapy follow-up and targeted …

Somastostatin (SS) scintigraphy (SRS) is an effective diagnostic tool for neuroendocrine
tumours (NET). High diagnostic accuracy is based on the high affinity binding between SS …

Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues is an
emerging and convincing treatment modality for patients with unresectable, somatostatin …

Five somatostatin receptor subtypes (sst) are known to date (sst1-5). Most neuroendocrine
tumors (NETs) feature a strong overexpression of these receptors, mainly of subtype 2 (sst2) …

Since the discovery of somatostatin (sst) in 1973, numerous chemical and biological studies
have been carried out to develop sst analogs with enhanced resistance to proteases and …